Mark Donoghoe

Dr Mark Donoghoe

Biostatistics and Databases Program
E-mail
m.donoghoe@unsw.edu.au
Cayrol J; Wakefield CE; Ilbawi A; Donoghoe M; Hoffman R; Echodu M; Schilstra C; Ortiz R; Wiener L, 2024, 'The lived experience of people affected by cancer: A global cross-sectional survey protocol', PLoS ONE, 19, pp. e0294492, http://dx.doi.org/10.1371/journal.pone.0294492
2024
Body A; Donoghoe MW; Ahern ES; Lal L; Downie P; Leahy MF; Fuentes-Bolanos N; Anazodo A; Padhye B; Hamad N; Wakefield CE; Segelov E, 2023, '2106P Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer', Annals of Oncology, 34, pp. S1104 - S1104, http://dx.doi.org/10.1016/j.annonc.2023.09.888
2023
Wakefield CE; Hetherington K; Robertson EG; Donoghoe MW; Hunter JD; Vetsch J; Marron JM; Tucker KM; Marshall GM; Broom A; Haber M; Tyrrell V; Malkin D; Lau L; Mateos MK; O’Brien TA; Ziegler DS, 2023, 'Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives', British Journal of Cancer, 129, pp. 1634 - 1644, http://dx.doi.org/10.1038/s41416-023-02429-1
2023
Gereis JM; Hetherington K; Robertson EG; Daly R; Donoghoe MW; Ziegler DS; Marshall GM; Lau LMS; Marron JM; Wakefield CE, 2023, 'Parents’ and adolescents’ perspectives and understanding of information about childhood cancer precision medicine', Cancer, 129, pp. 3645 - 3655, http://dx.doi.org/10.1002/cncr.34914
2023
Spitzer H; Berry S; Donoghoe M; Pelkmans L; Theis FJ, 2023, 'Learning consistent subcellular landmarks to quantify changes in multiplexed protein maps', Nature Methods, 20, pp. 1058 - 1069, http://dx.doi.org/10.1038/s41592-023-01894-z
2023
McGill BC; Wakefield CE; Tucker KM; Daly RA; Donoghoe MW; Vetsch J; Warby M; Fuentes-Bolanos NA; Barlow-Stewart K; Kirk J; Courtney E; O’Brien TA; Marshall GM; Pinese M; Cowley MJ; Tyrrell V; Deyell RJ; Ziegler DS; Hetherington K, 2023, 'Parents’ expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial', Cancer, 129, pp. 3620 - 3632, http://dx.doi.org/10.1002/cncr.34917
2023
Craig AT; Leong RNF; Donoghoe MW; Muscatello D; Mojica VJC; Octavo CJM, 2023, 'Comparison of statistical methods for the early detection of disease outbreaks in small population settings', IJID Regions, 8, pp. 157 - 163, http://dx.doi.org/10.1016/j.ijregi.2023.08.007
2023
LEUNG ONG K; O'CONNELL RL; JANUSZEWSKI AS; DONOGHOE MW; GEBSKI VAL; SULLIVAN D; ANN RYE K; SCOTT RS; BEST JD; TASKINEN M-R; SIMES RJ; JENKINS A; KEECH AC, 2023, '1350-P: Risk Models for the Development of Cardiovascular and Microvascular Events in Adults with Type 2 Diabetes in the FIELD Study', Diabetes, 72, http://dx.doi.org/10.2337/db23-1350-p
2023
Shamsa A; Gilchrist RB; Robertson DM; Rodgers RJ; Donoghoe MW; Ledger WL; Abbott JA; Riepsamen AH, 2023, 'Oocyte-Secreted Serum Biomarkers GDF9 and BMP15 in Women with Endometriosis', Reproductive Sciences, 30, pp. 1521 - 1527, http://dx.doi.org/10.1007/s43032-022-01107-6
2023
Riepsamen AH; Donoghoe MW; Indran IR; Hechtman L; Robertson DM; Gilchrist RB; Ledger WL; Yong EL, 2023, 'Serum GDF9 and BMP15 as potential markers of ovarian function in women with and without polycystic ovary syndrome', Clinical Endocrinology, 98, pp. 567 - 577, http://dx.doi.org/10.1111/cen.14851
2023
RIEPSAMEN AH; DONOGHOE MW; INDRAN IR; LIEN S; HECHTMAN L; ROBERTSON DM; GILCHRIST RB; YONG E-L; LEDGER WL, 2022, 'Serum GDF9 and BMP15 as Markers of Ovarian Function in Healthy Women and Women with Polycystic Ovary Syndrome', Fertility & Reproduction, 04, pp. 141 - 141, http://dx.doi.org/10.1142/s266131822274053x
2022
Schilstra CE; McCleary K; Fardell JE; Donoghoe MW; McCormack E; Kotecha RS; Lourenco RDA; Ramachandran S; Cockcroft R; Conyers R; Cross S; Dalla-Pozza L; Downie P; Revesz T; Osborn M; Alvaro F; Wakefield CE; Marshall GM; Mateos MK; Trahair TN, 2022, 'Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia', BMC Cancer, 22, pp. 985, http://dx.doi.org/10.1186/s12885-022-10072-x
2022
Hetherington K; Wakefield CE; Kunalan KPK; Donoghoe MW; McGill BC; Fardell JE; Daly R; Deyell RJ; Ziegler DS, 2022, 'Quality of Life (QoL) of Children and Adolescents Participating in a Precision Medicine Trial for High-Risk Childhood Cancer', Cancers, 14, http://dx.doi.org/10.3390/cancers14215310
2022
Donoghoe MW; Marschner IC, 2022, 'Parameter expansion for fitting regression models with non-negativity constraints', Communications in Statistics: Simulation and Computation, http://dx.doi.org/10.1080/03610918.2022.2154791
2022
Riepsamen AH; Donoghoe MW; Baerwald A; Pankhurst MW; Lien S; Chong YH; Robertson DM; Ledger WL; Gilchrist RB, 2021, 'Exploratory analysis of serum concentrations of oocyte biomarkers growth differentiation factor 9 and bone morphogenetic protein 15 in ovulatory women across the menstrual cycle', Fertility and Sterility, 116, pp. 546 - 557, http://dx.doi.org/10.1016/j.fertnstert.2021.02.001
2021
Riepsamen AH; Donoghoe MW; Baerwald A; Pankhurst MW; Lien S; Chong YH; Robertson DM; Ledger WL; Gilchrist RB, 2021, 'Serum Concentrations of GDF9 and BMP15 Across the Menstrual Cycle', Journal of the Endocrine Society, 5, pp. A734 - A735, http://dx.doi.org/10.1210/jendso/bvab048.1494
2021
Hsu J; Sansom-Daly UM; Hetherington K; Ellis SJ; Donoghoe MW; Cohn RJ; Zentella-Tusie A; Wakefield CE, 2021, 'Health service and medication use of parents of childhood cancer survivors: a controlled comparison study', Acta Oncologica, 60, pp. 1325 - 1334, http://dx.doi.org/10.1080/0284186X.2021.1955968
2021
Sansom‐daly UM; Wakefield CE; Ellis SJ; McGill BC; Donoghoe MW; Butow P; Bryant RA; Sawyer SM; Patterson P; Anazodo A; Plaster M; Thompson K; Holland L; Osborn M; Maguire F; O’dwyer C; Lourenco RDA; Cohn RJ; Sansom-Daly U, 2021, 'Online, group‐based psychological support for adolescent and young adult cancer survivors: Results from the recapture life randomized trial', Cancers, 13, pp. 2460, http://dx.doi.org/10.3390/cancers13102460
2021
Sansom‐daly UM; Wakefield CE; Signorelli C; Donoghoe MW; Anazodo A; Sawyer SM; Osborn M; Viney R; Daniell N; Faasse K; Cohn RJ; Sansom-Daly U, 2021, 'Patterns and predictors of healthcare use among adolescent and young adult cancer survivors versus a community comparison group', Cancers, 13, pp. 5270, http://dx.doi.org/10.3390/cancers13215270
2021
Wakefield CE; Sansom‐daly UM; McGill BC; Hetherington K; Ellis SJ; Robertson EG; Donoghoe MW; McCarthy M; Kelada L; Girgis A; King M; Grootenhuis M; Anazodo A; Patterson P; Lowe C; Dalla‐pozza L; Miles G; Cohn RJ; Sansom-Daly U, 2021, 'Providing psychological support to parents of childhood cancer survivors: ‘cascade’ intervention trial results and lessons for the future', Cancers, 13, pp. 5597, http://dx.doi.org/10.3390/cancers13225597
2021
Kamaladasa DS; Sansom-Daly UM; Hetherington K; McGill BC; Ellis SJ; Kelada L; Donoghoe MW; Evans H; Anazodo A; Patterson P; Cohn RJ; Wakefield CE, 2021, 'How Are Families Faring? Perceived Family Functioning among Adolescent and Young Adult Cancer Survivors in Comparison to Their Peers', Journal of Adolescent and Young Adult Oncology, 10, pp. 711 - 719, http://dx.doi.org/10.1089/jayao.2020.0215
2021
Barbour AP; Samra JS; Haghighi KS; Donoghoe MW; Burge M; Harris MT; Chua YJ; Mitchell J; O’Rourke N; Chan H; Gebski VJ; Gananadha S; Croagh DG; Kench JG; Goldstein D; Barbour A; Goldstein D; Samra JS; Harris M; Chua YJ; Yip S; Simes J; Hicks R; Coates A; Gurney H; Do V; Marschner I; Mitchell J; Donoghoe M; Goldstone S; Yip S; Chua YJ; Pavlakis N; Goldstein D; Aghmesheh M; Joubert W; Grimes D; Harris M; Burge M; Bagia S; Jaber M; Gananadha S; Bryant R; Nathanson L; Cavallucci D; Barbour A; Fawcett J; O’Rourke T; Croagh D; Jones R, 2020, 'The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer', Annals of Surgical Oncology, 27, pp. 2506 - 2515, http://dx.doi.org/10.1245/s10434-020-08205-2
2020
Barlow EL; Lambie N; Donoghoe MW; Naing Z; Hacker NF, 2020, 'The Clinical Relevance of p16 and p53 Status in Patients with Squamous Cell Carcinoma of the Vulva', Journal of Oncology, 2020, http://dx.doi.org/10.1155/2020/3739075
2020
Robertson EG; Wakefield CE; Cohn RJ; Battisti RA; Donoghoe MW; Ziegler DS; Fardell JE; Mitchell R; O'Brien TA, 2019, 'Piloting a parent and patient decision aid to support clinical trial decision making in childhood cancer', Psycho-Oncology, 28, pp. 1520 - 1529, http://dx.doi.org/10.1002/pon.5109
2019
Kelada L; Wakefield CE; Heathcote LC; Jaaniste T; Signorelli C; Fardell JE; Donoghoe M; McCarthy MC; Gabriel M; Cohn RJ, 2019, 'Perceived cancer-related pain and fatigue, information needs, and fear of cancer recurrence among adult survivors of childhood cancer', Patient Education and Counseling, 102, pp. 2270 - 2278, http://dx.doi.org/10.1016/j.pec.2019.06.022
2019
Stenson BJ; Donoghoe M; Brocklehurst P; Davis PG; Juszczak E; Marschner IC; Simes J; Tarnow-Mordi WO, 2019, 'Pulse Oximeter Saturation Targeting and Oximeter Changes in the Benefits of Oxygen Saturation Targeting (BOOST)-II Australia and BOOST-II UK Oxygen Trials', Journal of Pediatrics, 204, pp. 301 - 304.e2, http://dx.doi.org/10.1016/j.jpeds.2018.08.033
2019
Riepsamen AH; Chan K; Lien S; Sweeten P; Donoghoe MW; Walker G; Fraison EHJ; Stocker WA; Walton KL; Harrison CA; Ledger WL; Robertson DM; Gilchrist RB, 2019, 'Serum Concentrations of Oocyte-Secreted Factors BMP15 and GDF9 during IVF and in Women with Reproductive Pathologies', Endocrinology, 160, pp. 2298 - 2313, http://dx.doi.org/10.1210/en.2019-00264
2019
Donoghoe MW; Marschner IC, 2018, 'Logbin: An R package for relative risk regression using the log-binomial model', Journal of Statistical Software, 86, http://dx.doi.org/10.18637/jss.v086.i09
2018
Craig AT; Joshua CA; Sio AR; Donoghoe M; Betz-Stablein B; Bainivalu N; Dalipanda T; Kaldor J; Rosewell AE; Schierhout G, 2018, 'Epidemic surveillance in a low resource setting: Lessons from an evaluation of the Solomon Islands syndromic surveillance system, 2017', BMC Public Health, 18, pp. 1395, http://dx.doi.org/10.1186/s12889-018-6295-7
2018
Nowak A; Kok P-S; Livingstone A; Lesterhuis WJ; Yip S; Donoghoe M; Lam W-S; Stockler M, 2017, 'P2.06-025 DREAM - A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In', Journal of Thoracic Oncology, 12, pp. S1086 - S1087, http://dx.doi.org/10.1016/j.jtho.2016.11.1518
2017
Mitchell P; Siva S; Kok PS; O'Byrne K; Yeung A; Livingstone A; Donoghoe M; Yip S; Stockler MR, 2017, 'NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.', Journal of Clinical Oncology, 35, pp. TPS9097 - TPS9097, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.tps9097
2017
Donoghoe MW; Gebski V, 2017, 'The importance of censoring in competing risks analysis of the subdistribution hazard', BMC Medical Research Methodology, 17, pp. 52, http://dx.doi.org/10.1186/s12874-017-0327-3
2017
Williams KH; Sullivan DR; Nicholson GC; George J; Jenkins AJ; Januszewski AS; Gebski VJ; Manning P; Tan YM; Donoghoe MW; Ehnholm C; Young S; O'Brien R; Buizen L; Twigg SM; Keech AC, 2016, 'Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study', Metabolism: Clinical and Experimental, 65, pp. 783 - 793, http://dx.doi.org/10.1016/j.metabol.2015.12.008
2016
Donoghoe MW; Marschner IC, 2016, 'Estimation of adjusted rate differences using additive negative binomial regression', Statistics in Medicine, 35, pp. 3166 - 3178, http://dx.doi.org/10.1002/sim.6960
2016
Tarnow-Mordi W; Stenson B; Kirby A; Juszczak E; Donoghoe M; Deshpande S; Morley C; King A; Doyle LW; Fleck BW; Davis PG; Halliday HL; Hague W; Cairns P; Darlow BA; Fielder AR; Gebski V; Marlow N; Simmer K; Tin W; Ghadge A; Williams C; Keech A; Wardle SP; Kecskes Z; Kluckow M; Gole G; Evans N; Malcolm G; Luig M; Wright I; Stack J; Tan K; Pritchard M; Gray PH; Morris S; Headley B; Dargaville P; Simes RJ; Brocklehurst P, 2016, 'Outcomes of two trials of oxygen-saturation targets in preterm infants', New England Journal of Medicine, 374, pp. 749 - 760, http://dx.doi.org/10.1056/NEJMoa1514212
2016
Barbour A; O'Rourke N; Chan H; Chua YJ; Kench J; Hicks RJ; Samra JS; Pavlakis N; Haghighi KS; Yip S; Donoghoe M; Friend C; Burge ME; Fawcett J; Harris M; Aghmesheh M; Joubert WL; Gebski V; Simes J; Goldstein D, 2016, 'Initial survival outcomes for the AGITG GAP study - a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC)', JOURNAL OF CLINICAL ONCOLOGY, 34, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.4105
2016
Donoghoe MW; Marschner IC, 2015, 'Flexible regression models for rate differences, risk differences and relative risks', International Journal of Biostatistics, 11, pp. 91 - 108, http://dx.doi.org/10.1515/ijb-2014-0044
2015
Darlow BA; Marschner SL; Donoghoe M; Battin MR; Broadbent RS; Elder MJ; Hewson MP; Meyer MP; Ghadge A; Graham P; McNeill NJ; Kuschel CA; Tarnow-Mordi WO, 2014, 'Randomized controlled trial of oxygen saturation targets in very preterm infants: Two year outcomes', Journal of Pediatrics, 165, http://dx.doi.org/10.1016/j.jpeds.2014.01.017
2014
Donoghoe MW; Marschner IC, 2014, 'Stable computational methods for additive binomial models with application to adjusted risk differences', Computational Statistics and Data Analysis, 80, pp. 184 - 196, http://dx.doi.org/10.1016/j.csda.2014.06.019
2014
Blinman P; Gainford C; Donoghoe M; Martyn J; Blomfield P; Grant P; Kichenadasse G; Vaughan M; Brand A; Shannon C; Gebski V; Stockler M; Friedlander M, 2013, 'Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: An ANZGOG study', Journal of Gynecologic Oncology, 24, pp. 359 - 366, http://dx.doi.org/10.3802/jgo.2013.24.4.359
2013
Chan KH; O’Connell RL; Sullivan DR; Hoffmann LS; Rajamani K; Whiting M; Donoghoe MW; Vanhala M; Hamer A; Yu B; Stocker R; Ng MKC; Keech AC, 2013, 'Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study', Diabetologia, 56, pp. 724 - 736, http://dx.doi.org/10.1007/s00125-012-2818-4
2013
Stenson BJ; Tarnow-Mordi WO; Darlow BA; Simes J; Juszczak E; Askie L; Battin M; Bowler U; Broadbent R; Cairns P; Davis PG; Deshpande S; Donoghoe M; Doyle L; Fleck BW; Ghadge A; Hague W; Halliday HL; Hewson M; King A; Kirby A; Marlow N; Meyer M; Morley C; Simmer K; Tin W; Wardle SP; Brocklehurst P, 2013, 'Oxygen saturation and outcomes in preterm infants', New England Journal of Medicine, 368, pp. 2094 - 2104, http://dx.doi.org/10.1056/NEJMoa1302298
2013
Stanton K; Rao S; Assimes T; Wang B; McGee S; Harada R; Wilson A; Narasimhan B; Donoghoe M; Olin J; Cooke J; Ng M, 2012, 'Asymmetric Dimethylarginine (ADMA) Levels Correlate with Peripheral Vascular Disease Severity but not Coronary Artery Disease', Heart, Lung and Circulation, 21, pp. S11 - S11, http://dx.doi.org/10.1016/j.hlc.2012.05.034
2012
Ting R; Keech A; Drury P; Donoghoe M; Hedley J; Jenkins AJ; Davis T; Lehto S; Celermajer DS; Simes J; Kushwin R; Stanton K; Suranyi MG, 2012, 'Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment', Diabetes Care, 35, pp. 218 - 225, http://dx.doi.org/10.2337/dc11-1109
2012
Davis TME; Ting R; Best JD; Donoghoe MW; Drury PL; Sullivan DR; Jenkins AJ; O'Connell RL; Whiting MJ; Glasziou PP; Simes RJ; Kesäniemi YA; Gebski VJ; Scott RS; Keech AC, 2011, 'Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study', Diabetologia, 54, pp. 280 - 290, http://dx.doi.org/10.1007/s00125-010-1951-1
2011
Donoghoe MW; Gebski V, 2011, 'Impact of the censoring distribution on time-to-event problems in the presence of competing risks', Trials, 12, http://dx.doi.org/10.1186/1745-6215-12-s1-a140
2011
Ting R; Davis T; Drury P; Donoghoe M; Rajamani K; Best J; Kesaniemi Y; Keech A, 2011, 'Cardiovascular Risk, Renal Status and Fenofibrate Safety in the FIELD Study', Heart, Lung and Circulation, 20, pp. S202 - S202, http://dx.doi.org/10.1016/j.hlc.2011.05.497
2011
Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A, 2011, 'Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study', Diabetes Research and Clinical Practice, 94, pp. 284 - 290, http://dx.doi.org/10.1016/j.diabres.2011.07.028
2011
Scott R; Donoghoe M; Watts GF; O'Brien R; Pardy C; Taskinen MR; Davis TME; Colman PG; Manning P; Fulcher G; Keech AC, 2011, 'Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial', Cardiovascular Diabetology, 10, http://dx.doi.org/10.1186/1475-2840-10-102
2011
Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E, 2011, 'Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial', Gynecologic Oncology, 122, pp. 226 - 232, http://dx.doi.org/10.1016/j.ygyno.2011.04.019
2011
Rajamani K; Donoghoe M; Li L; Ting R-D; Colman P; Scott R; Laakso M; Keech A, 2010, 'FENOFIBRATE REDUCES PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES: THE FENOFIBRATE INTERVENTION AND EVENT LOWERING IN DIABETES (FIELD) STUDY', ATHEROSCLEROSIS SUPPLEMENTS, 11, pp. 219 - 220, http://dx.doi.org/10.1016/S1567-5688(10)71046-1
2010
Ting R-D; Davis TME; Drury PL; Donoghoe M; Rajamani K; Best JD; Kesaniemi YA; Keech AC, 2010, 'MS544 CARDIOVASCULAR AND RENAL SAFETY OF FENOFIBRATE IN THE FIELD STUDY', Atherosclerosis Supplements, 11, pp. 219 - 219, http://dx.doi.org/10.1016/s1567-5688(10)71044-8
2010
Sullivan D; Donoghoe M; Simes J; George J; Keech T, 2009, 'Abstract: P496 LONG-TERM FENOFIBRATE USE IS ASSOCIATED WITH REDUCED PREVALENCE OF LIVER ENZYME ELEVATION IN THE FIELD STUDY', Atherosclerosis Supplements, 10, pp. e809 - e809, http://dx.doi.org/10.1016/s1567-5688(09)70791-3
2009
Nagabushan S; Hamayun M; Fardell JE; Donoghoe M; Bland E; Bye A; Jacobson E; Manoharan N; Ziegler DS; McLoone JK; Johnson AM; Cohn RJ, 2023, 'LGG-11. COGNITIVE, ACADEMIC, AND QUALITY OF LIFE OUTCOMES IN SURVIVORS OF PEDIATRIC LOW-GRADE GLIOMA: CHALLENGING THE ‘BENIGN TUMOR’ PERCEPTION', in Neuro-Oncology, Oxford University Press (OUP), Vol. 25, pp. i57 - i58, http://dx.doi.org/10.1093/neuonc/noad073.221
2023
McLoone J; Signorelli C; Wakefield CE; Donoghoe M; Johnston K; Bell R; Cohn RJ, 2022, 'The 'ENGAGE' program: Effective childhood cancer survivorship care', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 80 - 80, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000871956500081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2022
Body A; Wakefield C; Luong VTT; Donoghoe M; Fuentes Bolanos NA; Anazodo A; Ho C; Grech L; Ahern ES; Segelov E, 2022, 'Patient-reported toxicity and quality of life following Sars-CoV-2 vaccination in adults and children with cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. LBA12068 - LBA12068, http://dx.doi.org/10.1200/jco.2022.40.17_suppl.lba12068
2022
Robertson E; Wakefield C; Cohn R; Robert B; Donoghoe M; Ziegler D; Fardell J; Mitchell R; O'Brien T, 2019, 'Delta: A Parent and Patient Decision Aid to Support Clinical Trial Decision-Making in Childhood Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S118 - S118, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458001090&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Barbour A; O'Rourke N; Chandrasegaram MD; Chua YJ; Kench J; Samra JS; Pavlakis N; Haghighi KS; Yip S; Fawcett J; Donoghoe M; Walker K; Burge ME; Gananadha S; Harris M; Aghmesheh M; Joubert WL; Gebski V; Simes J; Goldstein D, 2015, 'A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.4115
2015
Spitzer H; Berry S; Donoghoe M; Pelkmans L; Theis F, 2022, Learning consistent subcellular landmarks to quantify changes in multiplexed protein maps, , http://dx.doi.org/10.1101/2022.05.07.490900
2022
Body A; Wakefield C; Vi TTL; Donoghoe M; Bolanos NAF; Anazodo A; Ho C; Grech L; Ahern ES; Segelov E, 2022, 'Patient-reported toxicity and quality of life following Sars-CoV-2 vaccination in adults and children with cancer', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000891791500044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2022
Mitchell P; Siva S; Kok PS; O'Byrne K; Yeung A; Livingstone A; Donoghoe M; Yip S; Stockier MR, 2017, 'NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.9097
2017
Stanton KM; Rao SD; Assimes T; Wang B-Y; McGee S; Harada RK; Wilson A; Narasimhan B; Donoghoe M; Brown C; Keech A; Olin JW; Cooke JP; Ng MK, 2012, 'Plasma Asymmetric Dimethylarginine Levels Correlate with Peripheral Arterial Disease Severity but not Coronary Artery Disease', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885006387&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2012
Ting R; Donoghoe M; Jenkins AJ; Hedley J; Rajamani K; Drury PL; Davis TME; Celermajer D; Simes RJ; Keech AC, 2011, 'Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes mellitus and renal impairment - the FIELD study', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 323 - 324, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208702703033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Ting R; Davis TME; Jenkins AJ; Drury PL; Donoghoe MW; Rajamani JK; Kesaniemi AY; Best JD; Keech AC, 2011, 'Association of renal status and cardiovascular risk, and safety of fenofibrate in renal impairment in the FIELD study of 9,795 subjects with type 2 diabetes', in DIABETOLOGIA, SPRINGER, PORTUGAL, Lisbon, pp. S24 - S24, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), PORTUGAL, Lisbon, 12 September 2011 - 16 September 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307671300042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Keech AC; Rajamani JK; Best JD; Hankey G; Donoghoe MW; Li L; Jenkins AJ; Ting R; Davis TME; Phillips P; Barter P, 2011, 'Predictors of peripheral neuropathy and effects of fenofibrate among 9,795 subjects with type 2 diabetes: the fenofibrate intervention and event lowering in diabetes (FIELD) study', in DIABETOLOGIA, SPRINGER, PORTUGAL, Lisbon, pp. S81 - S82, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), PORTUGAL, Lisbon, 12 September 2011 - 16 September 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307671300181&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Keech AC; Alicia J; Whiting M; Barter P; Sullivan DR; Donoghoe M; Januszewski A; Karschimkus C; Blankenberg S; Simes J; Scott R; Laakso M; Taskinen M-R; Best JD, 2010, 'Novel Cardiovascular Risk Factor Prediction of Cardiovascular Events in the (Type 2 Diabetes) FIELD Study and Effects of Fenofibrate', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208231602961&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2010
Sullivan D; Donoghoe M; Simes J; George J; Keech T, 2009, 'LONG-TERM FENOFIBRATE USE IS ASSOCIATED WITH REDUCED PREVALENCE OF LIVER ENZYME ELEVATION IN THE FIELD STUDY', in ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER IRELAND LTD, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000207957101492&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Nowak A; Kok P-S; Livingstone A; Lesterhuis WJ; Yip S; Donoghoe M; Lam W-S; Stockler M, 2017, 'DREAM - A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In', Vol. 12, pp. S1086 - S1087, http://dx.doi.org/10.1016/j.jtho.2016.11.1518
2017